{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T20:13:34Z","timestamp":1769199214596,"version":"3.49.0"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"Supplement_K","license":[{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Watermeadow Medical"},{"name":"Ashfield Company"},{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Guidelines exist for management of pulmonary arterial hypertension (PAH), but information is limited for certain patient subgroups, including adults with portopulmonary hypertension (PoPH) or with PAH associated with congenital heart disease (PAH-CHD). This article discusses screening, clinical management, and prognosis in PoPH and PAH-CHD and, as such, considers the most recent clinical data and expert advice. A multidisciplinary consultation and follow-up by specialists are crucial for management of both PoPH and PAH-CHD, but each condition presents with unique challenges. Development of PoPH most commonly occurs among patients with liver cirrhosis. Initially, patients may be asymptomatic for PoPH and, if untreated, survival with PoPH is generally worse than with idiopathic PAH (IPAH), so early identification with screening is crucial. PoPH can be managed with PAH-specific pharmacological therapy, and resolution is possible in some patients with liver transplantation. With PAH-CHD, survival rates are typically higher than with IPAH but vary across the four subtypes: Eisenmenger syndrome, systemic-to-pulmonary shunts, small cardiac defects, and corrected defects. Screening is also crucial and, in patients who undergo correction of CHD, the presence of PAH should be assessed immediately after repair and throughout their long-term follow-up, with frequency of assessments determined by the patient\u2019s characteristics at the time of correction. Early screening for PAH in patients with portal hypertension or CHD, and multidisciplinary management of PoPH or PAH-CHD are important for the best patient outcomes.<\/jats:p>","DOI":"10.1093\/eurheartj\/suz221","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T09:07:51Z","timestamp":1576573671000},"page":"K37-K45","source":"Crossref","is-referenced-by-count":19,"title":["Pulmonary arterial hypertension populations of special interest: portopulmonary hypertension and pulmonary arterial hypertension associated with congenital heart disease"],"prefix":"10.1093","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6862-8975","authenticated-orcid":false,"given":"Laurent","family":"Savale","sequence":"first","affiliation":[{"name":"Facult\u00e9 de M\u00e9dicine, Universit\u00e9 Paris-Sud, Facult\u00e9 de M\u00e9decine, Universit\u00e9 Paris-Saclay, Le Kremlin-Bic\u00eatre, France"},{"name":"INSERM UMR_S 999, H\u00f4pital Marie Lannelongue, 92350 Le Plessis-Robinson, France"},{"name":"Service de Pneumologie, Centre de R\u00e9f\u00e9rence de l'Hypertension Pulmonaire S\u00e9v\u00e8re, DHU Thorax Innovation, H\u00f4pital Bic\u00eatre, AP-HP, Le Kremlin-Bic\u00eatre, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4081-6285","authenticated-orcid":false,"given":"Alessandra","family":"Manes","sequence":"additional","affiliation":[{"name":"Cardiothoracic Department, S. Orsola University Hospital, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"key":"2019121704072910800_suz221-B1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"key":"2019121704072910800_suz221-B2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","article-title":"Bosentan randomized trial of endothelin antagonist therapy I. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study","volume":"114","author":"Gali\u00e8","year":"2006","journal-title":"Circulation"},{"key":"2019121704072910800_suz221-B3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCULATIONAHA.118.033575","article-title":"Evaluation of macitentan in patients with Eisenmenger syndrome","volume":"139","author":"Gatzoulis","year":"2019","journal-title":"Circulation"},{"key":"2019121704072910800_suz221-B4","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S2213-2600(19)30091-8","article-title":"Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial","volume":"7","author":"Sitbon","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2019121704072910800_suz221-B5","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1183\/09031936.00209914","article-title":"Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights","volume":"46","author":"Dardi","year":"2015","journal-title":"Eur Respir J"},{"key":"2019121704072910800_suz221-B6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000084727","article-title":"Liver transplantation as ultimate tool to treat portal hypertension","volume":"23","author":"Klupp","year":"2005","journal-title":"Dig Dis"},{"key":"2019121704072910800_suz221-B7","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1378\/chest.11-0160","article-title":"Portopulmonary hypertension: a report from the US-based REVEAL Registry","volume":"141","author":"Krowka","year":"2012","journal-title":"Chest"},{"key":"2019121704072910800_suz221-B8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3350\/cmh.2014.20.1.6","article-title":"Hepatic venous pressure gradient: clinical use in chronic liver disease","volume":"20","author":"Suk","year":"2014","journal-title":"Clin Mol Hepatol"},{"key":"2019121704072910800_suz221-B9","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2019121704072910800_suz221-B10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1378\/chest.11-3241","article-title":"Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis","volume":"144","author":"Poms","year":"2013","journal-title":"Chest"},{"key":"2019121704072910800_suz221-B11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1183\/09031936.00117511","article-title":"Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension","volume":"41","author":"Savale","year":"2013","journal-title":"Eur Respir J"},{"key":"2019121704072910800_suz221-B12","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1164\/rccm.200804-613OC","article-title":"Portopulmonary hypertension: survival and prognostic factors","volume":"178","author":"Le Pavec","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2019121704072910800_suz221-B13","first-page":"35","article-title":"Pulmonary vascular complications in portal hypertension and liver disease: a concise review","volume":"78","author":"Porres-Aguilar","year":"2013","journal-title":"Rev Gastroenterol Mex"},{"key":"2019121704072910800_suz221-B14","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/0016-5085(91)90225-A","article-title":"Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics","volume":"100","author":"Hadengue","year":"1991","journal-title":"Gastroenterology"},{"key":"2019121704072910800_suz221-B15","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00408-013-9501-5","article-title":"Early initiation of prostacyclin in portopulmonary hypertension: 10 years of a transplant center's experience","volume":"191","author":"Awdish","year":"2013","journal-title":"Lung"},{"key":"2019121704072910800_suz221-B16","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/hep.28990","article-title":"Long-term outcome in liver transplantation candidates with portopulmonary hypertension","volume":"65","author":"Savale","year":"2017","journal-title":"Hepatology"},{"key":"2019121704072910800_suz221-B17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jacc.2011.03.026","article-title":"Cardiovascular risk assessment of the liver transplant candidate","volume":"58","author":"Raval","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2019121704072910800_suz221-B18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/ctr.12643","article-title":"Patent foramen ovale in liver transplant recipients does not negatively impact short-term outcomes","volume":"30","author":"Werlang","year":"2016","journal-title":"Clin Transplant"},{"key":"2019121704072910800_suz221-B19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.14503\/THIJ-16-6027","article-title":"Potential role of patent foramen ovale in exacerbating hypoxemia in chronic pulmonary disease","volume":"44","author":"Layoun","year":"2017","journal-title":"Tex Heart Inst J"},{"key":"2019121704072910800_suz221-B20","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.healun.2016.12.014","article-title":"Survival in portopulmonary hypertension: outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry","volume":"36","author":"Sithamparanathan","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"2019121704072910800_suz221-B21","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1600-6143.2006.01701.x","article-title":"The impact of treatment of portopulmonary hypertension on survival following liver transplantation","volume":"7","author":"Ashfaq","year":"2007","journal-title":"Am J Transplant"},{"key":"2019121704072910800_suz221-B22","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02148-2018","article-title":"An overview of the 6th world symposium on pulmonary hypertension","volume":"53","author":"Gali\u00e8","year":"2019","journal-title":"Eur Respir J"},{"key":"2019121704072910800_suz221-B23","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1378\/chest.11-2378","article-title":"Portopulmonary hypertension: light at the end of the tunnel?","volume":"141","author":"Sitbon","year":"2012","journal-title":"Chest"},{"key":"2019121704072910800_suz221-B24","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"key":"2019121704072910800_suz221-B25","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"2019121704072910800_suz221-B26","doi-asserted-by":"crossref","first-page":"204589401876930.","DOI":"10.1177\/2045894018769305","article-title":"Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1\/-2 studies","volume":"8","author":"Cartin-Ceba","year":"2018","journal-title":"Pulm Circ"},{"key":"2019121704072910800_suz221-B27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1378\/chest.10-0574","article-title":"Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension","volume":"139","author":"Cartin-Ceba","year":"2011","journal-title":"Chest"},{"key":"2019121704072910800_suz221-B28","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/hep.510300307","article-title":"Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension","volume":"30","author":"Krowka","year":"1999","journal-title":"Hepatology"},{"key":"2019121704072910800_suz221-B29","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/lt.21997","article-title":"Acute and long-term effects of inhaled iloprost in portopulmonary hypertension","volume":"16","author":"Melgosa","year":"2010","journal-title":"Liver Transpl"},{"key":"2019121704072910800_suz221-B30","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1155\/2015\/810376","article-title":"Effectiveness of phosphodiesterase-5 inhibitor therapy for portopulmonary hypertension","volume":"22","author":"Fisher","year":"2015","journal-title":"Can Respir J"},{"key":"2019121704072910800_suz221-B31","first-page":"PA3081","article-title":"Survival in portopulmonary hypertension (PoPH) in the era of modern PAH-targeted therapy","volume":"52","author":"Savale","year":"2018","journal-title":"Eur Respir J"},{"key":"2019121704072910800_suz221-B32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2005.10.013","article-title":"Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension","volume":"130","author":"Provencher","year":"2006","journal-title":"Gastroenterology"},{"key":"2019121704072910800_suz221-B33","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1183\/13993003.01376-2015","article-title":"Pulmonary arterial hypertension in patients treated with interferon","volume":"46","author":"Savale","year":"2015","journal-title":"Eur Respir J"},{"key":"2019121704072910800_suz221-B34","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1183\/09031936.00057914","article-title":"Pulmonary arterial hypertension in patients treated with interferon","volume":"44","author":"Savale","year":"2014","journal-title":"Eur Respir J"},{"key":"2019121704072910800_suz221-B35","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.chest.2015.09.018","article-title":"Severe pulmonary arterial hypertension in patients treated for hepatitis C with sofosbuvir","volume":"149","author":"Renard","year":"2016","journal-title":"Chest"},{"key":"2019121704072910800_suz221-B36","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1055\/s-0037-1606251","article-title":"Portopulmonary hypertension","volume":"38","author":"Savale","year":"2017","journal-title":"Semin Respir Crit Care Med"},{"key":"2019121704072910800_suz221-B37","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1097\/TP.0000000000001229","article-title":"International Liver Transplant Society practice guidelines: diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension","volume":"100","author":"Krowka","year":"2016","journal-title":"Transplantation"},{"key":"2019121704072910800_suz221-B38","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1111\/ajt.12783","article-title":"MELD exceptions for portopulmonary hypertension: current policy and future implementation","volume":"14","author":"Goldberg","year":"2014","journal-title":"Am J Transplant"},{"key":"2019121704072910800_suz221-B39","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1016\/j.transproceed.2013.07.001","article-title":"Extracorporeal membrane oxygenation rescue therapy in a case of portopulmonary hypertension during liver transplantation: a case report","volume":"45","author":"Stratta","year":"2013","journal-title":"Transplant Proc"},{"key":"2019121704072910800_suz221-B40","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1183\/09059180.00007814","article-title":"The changing landscape of pulmonary arterial hypertension and implications for patient care","volume":"23","author":"Hoeper","year":"2014","journal-title":"Eur Respir Rev"},{"key":"2019121704072910800_suz221-B41","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ijcard.2014.04.072","article-title":"Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification","volume":"174","author":"van Riel","year":"2014","journal-title":"Int J Cardiol"},{"key":"2019121704072910800_suz221-B42","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ijcard.2014.09.024","article-title":"Pulmonary arterial hypertension associated with congenital heart disease: recent advances and future directions","volume":"177","author":"Gatzoulis","year":"2014","journal-title":"Int J Cardiol"},{"key":"2019121704072910800_suz221-B43","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/eurheartj\/eht072","article-title":"Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups","volume":"35","author":"Manes","year":"2014","journal-title":"Eur Heart J"},{"key":"2019121704072910800_suz221-B44","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1136\/heartjnl-2017-312881","article-title":"Arrhythmias in adult patients with congenital heart disease and pulmonary arterial hypertension","volume":"104","author":"Drakopoulou","year":"2018","journal-title":"Heart"},{"key":"2019121704072910800_suz221-B45","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/eurheartj\/eht437","article-title":"Pulmonary hypertension related to congenital heart disease: a call for action","volume":"35","author":"Dimopoulos","year":"2014","journal-title":"Eur Heart J"},{"key":"2019121704072910800_suz221-B46","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1093\/eurheartj\/ehl116","article-title":"Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study","volume":"27","author":"Diller","year":"2006","journal-title":"Eur Heart J"},{"key":"2019121704072910800_suz221-B47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00019501-200502000-00004","article-title":"The remarkable right ventricle of patients with Eisenmenger syndrome","volume":"16","author":"Hopkins","year":"2005","journal-title":"Coron Artery Dis"},{"key":"2019121704072910800_suz221-B48","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.prrv.2011.01.007","article-title":"Pulmonary complications of congenital heart disease","volume":"13","author":"Healy","year":"2012","journal-title":"Paediatr Respir Rev"},{"key":"2019121704072910800_suz221-B49","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"key":"2019121704072910800_suz221-B50","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial","volume":"371","author":"Gali\u00e8","year":"2008","journal-title":"Lancet"},{"key":"2019121704072910800_suz221-B51","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2019121704072910800_suz221-B52","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N Engl J Med"},{"key":"2019121704072910800_suz221-B53","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1183\/13993003.02044-2014","article-title":"Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension","volume":"46","author":"McLaughlin","year":"2015","journal-title":"Eur Respir J"},{"key":"2019121704072910800_suz221-B54","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1136\/heartjnl-2015-307832","article-title":"Riociguat for pulmonary arterial hypertension associated with congenital heart disease","volume":"101","author":"Rosenkranz","year":"2015","journal-title":"Heart"},{"key":"2019121704072910800_suz221-B55","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.1375","article-title":"Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study","volume":"21","author":"Beghetti","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2019121704072910800_suz221-B56","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/CIRCULATIONAHA.109.883876","article-title":"Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension","volume":"121","author":"Dimopoulos","year":"2010","journal-title":"Circulation"},{"key":"2019121704072910800_suz221-B57","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"N Engl J Med"},{"key":"2019121704072910800_suz221-B58","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/21\/Supplement_K\/K37\/31538853\/suz221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/21\/Supplement_K\/K37\/31538853\/suz221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T17:05:09Z","timestamp":1613149509000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/21\/Supplement_K\/K37\/5678710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":58,"journal-issue":{"issue":"Supplement_K","published-online":{"date-parts":[[2019,12,17]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/suz221","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,12,1]]}}}